PA007423.m2a: Non-conjugated Recombinant Anti-human CD19 Monoclonal Antibody (Clone: B43) for Flow Cytometry, Mouse IgG2a Kappa, In vivo Grade

Catalog No.: PA007423.m2a | **Product Name:** Recombinant Anti-human CD19 Monoclonal Antibody (Clone: B43), Mouse IgG2a Kappa

Recombinant mouse IgG2a isotype controls and Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

PRODUCT SPECIFICATIONS

Catalog No.	PA007423.m2a
Product Name	Recombinant Anti-human CD19 Monoclonal Antibody (Clone: B43), Mouse IgG2a Kappa
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	B-lymphocyte antigen CD19, Cluster of Differentiation 19, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, CVID3
Clone	B43.
Isotype	Mouse IgG2a kappa.
Source/Host	The recombinant anti-human CD19 monoclonal antibody (clone: B43) for Flow Cytometry was produced in mammalian cells.
Specificity/Sensitivity	The recombinant B43 antibody for Flow Cytometry specifically binds to the human CD19 protein.
Applications	Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F).
Form Of Antibody	0.2 uM filtered solution, pH 7.4, containing 0.09% sodium azide.
Endotoxin	Less than 1 EU/mg of protein as determined by LAL method.
Purity	>95% by SDS-PAGE under reducing conditions.
Shipping	The Recombinant Anti-human CD19 Monoclonal Antibody (Clone: B43) for Flow Cytometry, Mouse IgG2a Kappa is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, 2 to 8°C as supplied. Do not freeze it.

REFERENCES & BACKGROUND

The B43 antibody binds to the human CD19 protein, a transmembrane protein expressed in all B lineage cells including human plasma cells. CD19 plays two major roles in human B cells: it acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane, and works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for leukemia immunotherapies.